PMID- 36937051
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230321
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Electronic)
IS  - 2296-2360 (Linking)
VI  - 10
DP  - 2022
TI  - Severe pediatric asthma therapy: Omalizumab-A systematic review and meta-analysis 
      of efficacy and safety profile.
PG  - 1033511
LID - 10.3389/fped.2022.1033511 [doi]
LID - 1033511
AB  - BACKGROUND: Omalizumab is the first biological therapy used to treat 
      moderate-to-severe asthma and certainly the one with the highest number of 
      publications. METHODS: A systematic review and meta-analysis were performed to 
      examine two critical outcomes of omalizumab therapy, asthma exacerbation rate, 
      the reduction of the use of inhaled corticosteroids (ICS), and the improvement of 
      the lung function as a secondary outcome using the following keywords in the 
      MEDLINE database: "anti-IgE, severe asthma, children, and randomized controlled 
      trial." We specifically selected papers that included moderate-to-severe asthma 
      patients and collected data on children and adolescents. RESULTS: Four RCT 
      studies (total number of patients = 1,239) were included in the analysis. The 
      reported data on exacerbations showed an overall improvement in the exacerbation 
      rate with a decreased use of inhaled steroids and some other minimal clinically 
      important difference (MCID). CONCLUSIONS: Our systematic review confirms the 
      known findings that omalizumab therapy decreases asthma exacerbation rate and 
      reduces background therapy inhaled steroid dose. Therefore, add-on therapy with 
      omalizumab shows a good efficacy and safety profile, thus proving to be a useful 
      additional therapeutic option. SYSTEMATIC REVIEW REGISTRATION: 
      https://www.crd.york.ac.uk/prospero/, identifier: CRD42023396785.
CI  - (c) 2023 Fenu, La Tessa, Calogero and Lombardi.
FAU - Fenu, Grazia
AU  - Fenu G
AD  - Pediatric Pulmonary Unit, "Anna Meyer," IRCCS Pediatric University-Hospital, 
      Florence, Italy.
FAU - La Tessa, Andrea
AU  - La Tessa A
AD  - Pediatric Resident, University of Florence, Florence, Italy.
FAU - Calogero, Claudia
AU  - Calogero C
AD  - Pediatric Pulmonary Unit, "Anna Meyer," IRCCS Pediatric University-Hospital, 
      Florence, Italy.
FAU - Lombardi, Enrico
AU  - Lombardi E
AD  - Pediatric Pulmonary Unit, "Anna Meyer," IRCCS Pediatric University-Hospital, 
      Florence, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230303
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC10020639
OTO - NOTNLM
OT  - anti-IgE
OT  - children
OT  - randomized controlled trial
OT  - severe asthma
OT  - systematic review
COIS- GF, in the last 3 years, declares to have financial or non-financial support from 
      AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Sanofi. EL, in 
      the last 3 years, declares to have financial or non-financial support from 
      Abbvie, Angelini, Boehringer Ingelheim, Chiesi, Cosmed, GlaxoSmithKline, 
      Lusofarmaco, Novartis, Omron, Restech, Sanofi, Vertex, and Vifor. The remaining 
      authors declare that the research was conducted in the absence of any commercial 
      or financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2023/03/21 06:00
MHDA- 2023/03/21 06:01
PMCR- 2023/03/03
CRDT- 2023/03/20 03:57
PHST- 2022/08/31 00:00 [received]
PHST- 2022/12/30 00:00 [accepted]
PHST- 2023/03/20 03:57 [entrez]
PHST- 2023/03/21 06:00 [pubmed]
PHST- 2023/03/21 06:01 [medline]
PHST- 2023/03/03 00:00 [pmc-release]
AID - 10.3389/fped.2022.1033511 [doi]
PST - epublish
SO  - Front Pediatr. 2023 Mar 3;10:1033511. doi: 10.3389/fped.2022.1033511. eCollection 
      2022.